Evidence map›Paper›PMID 41498629›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

CsdA-LaeB Regulatory Hub Contributes to Aspergillus fumigatus Virulence via Fumiquinazoline C Biosynthesis.

Zili Song, Hongjiao Zhang, Leixin Ye, Yuxin Lei, Linqi Wang, Xiao Liu, Nayanna M Mercado Soto, Nancy P Keller, Berl R Oakley, Can Zhao and 5 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Repurposing FDA-Approved Drugs to Inhibit Fungal PPTases for Broad-Spectrum Synergy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zili SongState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.ORCID https://orcid.org/0000-0001-5087-8290
Hongjiao ZhangState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Leixin YeState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Yuxin LeiState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Linqi WangState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Xiao LiuState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Nayanna M Mercado SotoDepartment of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Nancy P KellerDepartment of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Berl R OakleyDepartment of Molecular Biosciences, University of Kansas, Lawrence, Kansas, USA.
Can ZhaoManchester Fungal Infection Group, Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
Michael BromleyManchester Fungal Infection Group, Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK.
Hongwei LiuState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Lei CaiState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Koon Ho WongMoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China.
Wen-Bing YinState Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.ORCID https://orcid.org/0000-0002-9184-3198

Funding

Chinese Academy of Sciences Project for Young Scientists in Basic Research YSBR-111National Key Research and Development Program of China 2022YFC2303000National Natural Science Foundation of China 32470046Strategic Priority Research Program of Chinese Academy of Sciences XDB0830000
6 · The paper itself

Abstract

Fungal secondary metabolism plays a critical role in pathogen-host interactions, yet the regulatory networks linking metabolic reprogramming to virulence remain poorly understood. This study identifies a conserved regulatory hub in the human pathogen Aspergillus fumigatus, where the RNA-binding protein (RBP) CsdA interacts with the global regulator LaeB in the nucleus to regulate biosynthesis of the secondary metabolite fumiquinazoline C (FqC). Disruption of the CsdA-LaeB interaction hyperactivates FqC production, enhancing fungal colonization and lethality in murine invasive aspergillosis models. Integrative metabolomic and transcriptomic analyses reveal that CsdA and LaeB function as co-regulators of a broader secondary metabolic gene cluster network, with FqC emerging as an effector that mediates virulence in vivo. Genetic validation confirms that FqC is strictly required for the increased virulence phenotype of CsdA- or LaeB-deficient strains, while analyses of clinical isolates demonstrate a striking inverse correlation: reduced CsdA and LaeB expression coincides with elevated FqC production, showing consistency with the infection outcomes of the deletion mutants. This work identifies the RBP-based interaction that regulates fungal metabolic virulence, shedding new light on the post-transcriptional regulatory logic linking secondary metabolism to pathogenicity and offering alternative strategies for diagnostic development and therapeutic intervention in invasive fungal diseases.

Indexed as

AspergillosisAspergillus fumigatusFungal ProteinsQuinazolinesRNA-Binding ProteinsAnimalsGene Expression Regulation, FungalMiceSecondary MetabolismVirulenceFungal ProteinsQuinazolinesRNA-Binding Proteinsclinical isolatesfungal virulencegene regulationRNA‐binding proteinsecondary metabolite

Identifiers

PMID41498629
PMCPMC13042810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.